&t

Margaret Johnson
;em>REFERENCE: Lancet 2007; 370:39-48
MARGARET JOHNSON, Royal Free Hospital, London
A new non-nucleoside reverse-transcriptase inhibitor has demonstrated its activity in patients infected with HIV-1. TMC125, or etravirine, was compared with placebo in over 500 treatment-experienced patients in the DUET-2 trial, and Derek Thorne heard more from Margaret Johnson of the Royal Free Hospital in London.
MARGARET JOHNSON, Royal Free Hospital, London
A new non-nucleoside reverse-transcriptase inhibitor has demonstrated its activity in patients infected with HIV-1. TMC125, or etravirine, was compared with placebo in over 500 treatment-experienced patients in the DUET-2 trial, and Derek Thorne heard more from Margaret Johnson of the Royal Free Hospital in London.
Audio clip: Adobe Flash Player (version 9 or above) is required to play this audio clip. Download the latest version here. You also need to have JavaScript enabled in your browser.